41. |
|
|
42. |
|
|
43. |
|
|
44. |
- Dias, J., et al.
(författare)
-
Surgical management of Dupuytren's contracture in Europe: regional analysis of a surgeon survey and patient chart review
- 2013
-
Ingår i: International Journal of Clinical Practice. - : Hindawi Limited. - 1742-1241 .- 1368-5031. ; 67:3, s. 271-281
-
Tidskriftsartikel (refereegranskat)abstract
- Aim We explored regional variations in the surgical management of patients with Dupuytren's contracture (DC) in 12 European countries using a surgeon survey and patient chart review. Methods Twelve countries participated: Denmark, Finland, Sweden (Nordic region); Czech Republic, Hungary, Poland (East); France, Germany, the Netherlands, UK (West); Italy, Spain (Mediterranean). For the survey, a random sample of orthopaedic/plastic surgeons (n=687) with 330years' experience was asked about DC procedures performed during the previous 12months. For the chart review (n=3357), information from up to five consecutive patients was extracted. Descriptive statistics are reported. Results Ninety-five per cent of all surgeons used fasciectomy for DC, followed by fasciotomy (70%), dermofasciectomy (38%) and percutaneous needle fasciotomy (35%). Most surgeons were satisfied with fasciectomy over other procedures. Recommended time away from work and duration of physical therapy increased with the invasiveness of the procedure. The intra-operative complication rate was 4.0%; the postoperative complication rate was 34%. Overall, 97% of the procedures were rated by surgeons as having a positive outcome. Across all regions, 54% of patients had no nodules or contracture after the procedures. Only 2% of patients required retreatment within the first year of surgery. Important inter- and intraregional differences in these aspects of patient management are described. Conclusions Understanding current regional treatment patterns and their relationships to country-specific health systems may facilitate earlier identification of, and intervention for, DD and help to optimise the overall treatment for patients with this chronic condition.
|
|
45. |
|
|
46. |
|
|
47. |
|
|
48. |
|
|
49. |
|
|
50. |
|
|